Form Type: 4

SEC EDGAR Link
Acccession Number:0001192482-19-000256
Date:2019-05-13
Issuer: RECRO PHARMA, INC. (REPH)
Original Submission Date:

Reporting Person:

HENWOOD GERALDINE
C/O RECRO PHARMA, INC.
490 LAPP ROAD MALVERN, PA 19355

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-05-13 M 123,500 a $2.47 342,947 direct
COMMON STOCK 2019-05-13 S 123,500 d $8.89 219,447 direct
COMMON STOCK 2019-05-13 S 21,306 d $8.89 198,141 direct
COMMON STOCK 0 $0.00 50,000 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
EMPLOYEE STOCK OPTION (RIGHT TO BUY) 2.47 2019-05-13 deemed execution date M 123,500 (d) 2024-12-17 common stock 123,500 $2.47 0 direct
Footnotes
IDfootnote
f1 the price reported in column 4 is a weighted average price. the shares were sold in multiple transactions at prices ranging from $8.78 to $8.98, inclusive. the reporting person undertakes to provide recro pharma, inc., any security holder of recro pharma, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 3 to this form 4.
f2 the sale reported in this form 4 was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $8.84 to $8.92, inclusive.
f4 the shares subject to this option are fully vested and exercisable.

Elevate your investments